SG11202102006YA - Crystalline forms of a quinazole compound and its hydrochloride salts - Google Patents
Crystalline forms of a quinazole compound and its hydrochloride saltsInfo
- Publication number
- SG11202102006YA SG11202102006YA SG11202102006YA SG11202102006YA SG11202102006YA SG 11202102006Y A SG11202102006Y A SG 11202102006YA SG 11202102006Y A SG11202102006Y A SG 11202102006YA SG 11202102006Y A SG11202102006Y A SG 11202102006YA SG 11202102006Y A SG11202102006Y A SG 11202102006YA
- Authority
- SG
- Singapore
- Prior art keywords
- quinazole
- compound
- crystalline forms
- hydrochloride salts
- hydrochloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862731500P | 2018-09-14 | 2018-09-14 | |
PCT/IB2019/057720 WO2020053816A1 (fr) | 2018-09-14 | 2019-09-12 | Formes cristallines d'un composé de quinazole et ses sels de chlorhydrate |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102006YA true SG11202102006YA (en) | 2021-04-29 |
Family
ID=69776732
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102006YA SG11202102006YA (en) | 2018-09-14 | 2019-09-12 | Crystalline forms of a quinazole compound and its hydrochloride salts |
SG11202101712XA SG11202101712XA (en) | 2018-09-14 | 2019-09-12 | Kits and methods for treating cancers |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101712XA SG11202101712XA (en) | 2018-09-14 | 2019-09-12 | Kits and methods for treating cancers |
Country Status (16)
Country | Link |
---|---|
US (2) | US11883402B2 (fr) |
EP (2) | EP3849964A4 (fr) |
JP (2) | JP2022500416A (fr) |
KR (2) | KR20210046818A (fr) |
CN (2) | CN112823153A (fr) |
AR (2) | AR116669A1 (fr) |
AU (2) | AU2019340598A1 (fr) |
BR (2) | BR112021004527A2 (fr) |
CA (2) | CA3111062A1 (fr) |
IL (2) | IL281167A (fr) |
MX (2) | MX2021002876A (fr) |
PH (2) | PH12021550432A1 (fr) |
SG (2) | SG11202102006YA (fr) |
TW (2) | TW202027750A (fr) |
UY (2) | UY38375A (fr) |
WO (2) | WO2020053816A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020053816A1 (fr) | 2018-09-14 | 2020-03-19 | Hanmi Pharmaceutical Co., Ltd. | Formes cristallines d'un composé de quinazole et ses sels de chlorhydrate |
CN114642728A (zh) * | 2021-06-02 | 2022-06-21 | 德琪(浙江)医药科技有限公司 | mTOR抑制剂的制药用途及其药物组合物 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2514092C (fr) * | 2003-01-21 | 2013-03-19 | S.S.C.I., Inc. | Nouvelle cocristallisation de sel d'acide chlorhydrique d'un agent actif |
KR100735639B1 (ko) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
AU2006217738A1 (en) | 2005-02-26 | 2006-08-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
WO2007140385A2 (fr) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Nouveaux composés en tant que ligands des récepteurs des cannabinoïdes et utilisations de ceux-ci |
CA2659307A1 (fr) * | 2006-07-28 | 2008-01-31 | Synthon B.V. | Forme cristalline d'erlobtinib |
EP2170844B1 (fr) | 2007-02-21 | 2016-05-04 | Natco Pharma Limited | Nouveaux polymorphes destinés de chlorhydrate d'erlotinibe et procédé de fabrication |
TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
KR101217526B1 (ko) | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
KR101317809B1 (ko) * | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
KR101272613B1 (ko) | 2011-10-05 | 2013-06-10 | 한미사이언스 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체 |
JP5894714B1 (ja) | 2013-03-06 | 2016-03-30 | アストラゼネカ アクチボラグ | 上皮成長因子受容体の活性化変異型のキナゾリン阻害剤 |
WO2015154725A1 (fr) * | 2014-04-11 | 2015-10-15 | 四川海思科制药有限公司 | Dérivé quinazoline, et son procédé de préparation et son utilisation en médecine |
CN106588943B (zh) | 2015-10-19 | 2018-10-16 | 广东东阳光药业有限公司 | 一种egfr抑制剂的盐、晶型及其用途 |
CA3040348A1 (fr) | 2016-10-19 | 2018-04-26 | United States Government As Represented By The Department Of Veterans Affairs | Compositions et methodes pour le traitement du cancer |
AU2017363199B2 (en) * | 2016-11-17 | 2023-08-17 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations |
WO2020053816A1 (fr) | 2018-09-14 | 2020-03-19 | Hanmi Pharmaceutical Co., Ltd. | Formes cristallines d'un composé de quinazole et ses sels de chlorhydrate |
-
2019
- 2019-09-12 WO PCT/IB2019/057720 patent/WO2020053816A1/fr unknown
- 2019-09-12 KR KR1020217010957A patent/KR20210046818A/ko unknown
- 2019-09-12 WO PCT/US2019/050843 patent/WO2020056156A1/fr unknown
- 2019-09-12 JP JP2021513941A patent/JP2022500416A/ja active Pending
- 2019-09-12 CN CN201980060170.XA patent/CN112823153A/zh active Pending
- 2019-09-12 BR BR112021004527-9A patent/BR112021004527A2/pt not_active Application Discontinuation
- 2019-09-12 CN CN201980060160.6A patent/CN112770758A/zh active Pending
- 2019-09-12 CA CA3111062A patent/CA3111062A1/fr active Pending
- 2019-09-12 SG SG11202102006YA patent/SG11202102006YA/en unknown
- 2019-09-12 US US17/275,382 patent/US11883402B2/en active Active
- 2019-09-12 MX MX2021002876A patent/MX2021002876A/es unknown
- 2019-09-12 BR BR112021004546-5A patent/BR112021004546A2/pt unknown
- 2019-09-12 JP JP2021514419A patent/JP2022500456A/ja active Pending
- 2019-09-12 EP EP19859287.5A patent/EP3849964A4/fr active Pending
- 2019-09-12 AU AU2019340598A patent/AU2019340598A1/en active Pending
- 2019-09-12 US US17/275,290 patent/US20220040180A1/en not_active Abandoned
- 2019-09-12 MX MX2021002875A patent/MX2021002875A/es unknown
- 2019-09-12 KR KR1020217010772A patent/KR20210061371A/ko unknown
- 2019-09-12 AU AU2019337640A patent/AU2019337640A1/en not_active Abandoned
- 2019-09-12 CA CA3110369A patent/CA3110369A1/fr active Pending
- 2019-09-12 EP EP19860538.8A patent/EP3849557A4/fr not_active Withdrawn
- 2019-09-12 SG SG11202101712XA patent/SG11202101712XA/en unknown
- 2019-09-16 UY UY0001038375A patent/UY38375A/es not_active Application Discontinuation
- 2019-09-16 TW TW108133290A patent/TW202027750A/zh unknown
- 2019-09-16 TW TW108133291A patent/TW202023562A/zh unknown
- 2019-09-16 AR ARP190102610A patent/AR116669A1/es unknown
- 2019-09-16 UY UY0001038374A patent/UY38374A/es unknown
- 2019-09-16 AR ARP190102611A patent/AR116406A1/es unknown
-
2021
- 2021-03-01 PH PH12021550432A patent/PH12021550432A1/en unknown
- 2021-03-01 IL IL281167A patent/IL281167A/en unknown
- 2021-03-01 IL IL281168A patent/IL281168A/en unknown
- 2021-03-03 PH PH12021550456A patent/PH12021550456A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283860A (en) | Crystalline forms and salt forms of a kinase inhibitor | |
EP3619208C0 (fr) | Formes cristallines d'un composé inhibiteur de jak | |
IL287668A (en) | Crystalline forms of btk inhibitor | |
IL283663A (en) | Crystalline forms of a compound for the treatment or prevention of rheumatism or hyperuricemia | |
IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
PL3613733T3 (pl) | Nowy krystaliczny stały chlorowodorek 3-fenylo-4-propylo-1-(pirydyn-2-ylo)-1H-pirazol-5-olu | |
EP3558315A4 (fr) | Sels cristallins et polymorphes d'un antagoniste de p2x3 | |
IL289929A (en) | Crystal forms of cd73 inhibitor | |
IL281168A (en) | Crystal forms of the quinazole compound and its hydrochloride salts | |
IL282996A (en) | Crystalline forms of a modified imidazopyridine compound and their use as P2X3 modulators | |
IL282454A (en) | Crystalline salts of plasma kallikrein inhibitor | |
IL274027A (en) | B-RAF kinase inhibitor salt crystals | |
IL272835A (en) | Salts of a compound and crystalline forms thereof | |
IL278054A (en) | The crystalline forms of a compound | |
IL279953A (en) | Crystal forms of LTA4H inhibitor | |
IL292206A (en) | The salts of a compound and its crystalline forms | |
SG11202107225SA (en) | Crystalline form of a cdk inhibitor | |
SG11202009262VA (en) | Salts of compounds and crystals thereof | |
IL274758A (en) | Crystalline forms of praquinostat | |
HK1252841A1 (zh) | 噻吩並嘧啶化合物的鹽酸鹽的結晶形式 | |
GB201912411D0 (en) | Crystalline forms of ivosidenib | |
IL285763A (en) | Solid polymorphs of the flana-binding compound and its hydrochloride salts | |
SG11202105355XA (en) | Crystalline salts of corydalmine | |
EP3630750A4 (fr) | Sels et formes cristallines d'un composé | |
IL292847A (en) | Crystalline forms of magl inhibitor |